Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT01915602
Title	Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
Recruitment	Completed
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Bayer
Indications	hepatocellular carcinoma
Therapies	Refametinib + Sorafenib
Age Groups:	adult
Covered Countries	USA \| TUR \| NZL \| ITA \| ISR \| HUN \| GBR \| FRA \| ESP \| DEU \| CZE \| CHE \| BEL \| AUT